Anthony P Adamis Net Worth

The estimated Net Worth of Anthony P Adamis is at least 32.9 千$ dollars as of 23 June 2024. Anthony Adamis owns over 2,000 units of EyePoint Pharmaceuticals Inc stock worth over 32,880$ and over the last 2 years Anthony sold EYPT stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Anthony Adamis EYPT stock SEC Form 4 insiders trading

Anthony has made over 2 trades of the EyePoint Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Anthony exercised 2,000 units of EYPT stock worth 16,440$ on 23 June 2024.

The largest trade Anthony's ever made was exercising 2,000 units of EyePoint Pharmaceuticals Inc stock on 23 June 2024 worth over 16,440$. On average, Anthony trades about 800 units every 73 days since 2022. As of 23 June 2024 Anthony still owns at least 4,000 units of EyePoint Pharmaceuticals Inc stock.

You can see the complete history of Anthony Adamis stock trades at the bottom of the page.

What's Anthony Adamis's mailing address?

Anthony's mailing address filed with the SEC is C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472.

Insiders trading at EyePoint Pharmaceuticals Inc

Over the last 6 years, insiders at EyePoint Pharmaceuticals Inc have traded over 67,100,515$ worth of EyePoint Pharmaceuticals Inc stock and bought 21,910,863 units worth 111,404,456$ . The most active insiders traders include Healthcare Partners, L.P.Ew...、Asset Management, Lp Chen B...、Ye Liu. On average, EyePoint Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of 1,746,068$. The most recent stock trade was executed by Goran Ando on 21 August 2024, trading 5,000 units of EYPT stock currently worth 39,750$.

What does EyePoint Pharmaceuticals Inc do?

psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®

Complete history of Anthony Adamis stock trades at EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc executives and stock owners

EyePoint Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Nancy Lurker,
  President, Chief Executive Officer, Director
• Nancy S. Lurker,
  Pres, CEO & Director
• Dario Paggiarino,
  Senior Vice President, Chief Medical Officer
• George Elston,
  Chief Financial Officer and Head of Corporate Development
• Dr. Dario A. Paggiarino,
  Sr. VP & Chief Medical Officer
• George O. Elston,
  CFO & Head of Corp. Devel.
• David Scott Jones,
  Sr. VP & Chief Commercial Officer
• Dr. Jay S. Duker M.D.,
  Chief Operating Officer
• Joseph Rayne,
  IR Contact Officer
• Kristine Peterson,
  Independent Director
• David Mazzo,
  Independent Director
• John Landis,
  Independent Director
• David Guyer,
  Independent Director
• Douglas Godshall,
  Independent Director
• Ronald Eastman,
  Independent Director
• Wendy DiCicco,
  Director
• Jay Duker,
  Chief Strategic Scientific Officer
• Said Saim,
  Chief Technology Officer
• Scott Jones,
  Senior Vice President, Chief Commercial Officer
• Ron Honig,
  Senior Vice President, General Counsel, Secretary
• Goran Ando,
  Independent Chairman of the Board
• Dr. Anna Kluczewska,
  CEO of AION Diagnostics Ltd, Pres of AION Diagnostics Ltd and Director of AION Diagnostics Ltd
• Dr. John Weet,
  Sr. VP of Regulatory
• Jennifer Leonard,
  Sr. VP of HR & IT
• Ron I. Honig Esq.,
  Sr. VP, Gen. Counsel & Company Sec.
• Said Saim,
  Chief Technology Officer
• Karen L. Zaderej,
  
• Leonard S Ross,
  See Remarks
• Asset Management, Lp Chen B...,
  
• Anthony P Adamis,
  
• Michael Craig Pine,
  Chief Corp Dev.&Strat. Officer
• Michael W Rogers,
  
• Healthcare Partners, L.P.Ew...,
  
• David Price,
  CFO
• James J Barry,
  Director
• Leonard M Blum,
  See Remarks
• Ramiro Ribeiro,
  Chief Medical Officer
• Ye Liu,
  
• Stuart Duty,
  
• Fred Hassan,